Published in AIDS Weekly, June 1st, 2009
"This was a 6-month, open-label, proof-of-principle pilot study. Metabolicward studies were performed before and 3 and 6 months after leptin treatment. Participants included eight HIV-infected men with lipoatrophy, fasting triglycerides greater than 300 mg/dl, and serum leptin less than 3 ng/ml. Recombinant human leptin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.